Roche To Start Phase 3 Study For Alzheimer's Prospect This Year After New Data From Phase 2

Roche Holdings AG (OTC:RHHBY) on Thursday presented new data at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases.

Highlights included presentations from the ongoing trontinemab Phase 1b/2a Brainshuttle AD study, which demonstrated dose-dependent rapid amyloid depletion from the brain and the potential of the Elecsys pTau181 plasma test to rule out amyloid pathology.

Also Read: Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death

Preliminary results for trontinemab from 114 participants in the 1.8 or 3.6 mg/kg suggest a rapid and deep, dose-dependent reduction of amyloid plaques in the brain as ...